HRMYHarmony Biosciences Holdings, Inc.
$40.31+24% 1Y
$40.31
$25.9052 weeks$42.88
The financials
Harmony Biosciences Holdings, Inc. by the numbers
Harmony Biosciences Holdings, Inc. (HRMY) reported revenue of $261M in Q2 2026 (quarter ended Jun 30, 2026), up 30% from the same quarter a year earlier. That came with a gross margin of 76% and net income of $75M (29% of revenue). For the full year FY2025, revenue was $868M (+22% year on year) and net income $159M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $261M | $200M | +30% |
| Gross profit | $198M | $162M | +22% |
| Operating income | $89M | $48M | +85% |
| Net income | $75M | $40M | +90% |
| Diluted EPS | $1.28 | $0.68 | +88% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $261.3M (+21%)
Rare Neurological Diseases grew +30% year on year
Segment Latestquarter on quarteryear on year
- Rare Neurological Diseases$261.3M$261.3Mquarter on quarter +21%year on year +30%+21%+30%
On our screens:Stocks with no debt